Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | An update on camidanlumab tesirine in HL

Alex Herrera • 29 Sep 2022
SOHO 2022
Hodgkin Lymphoma Lymphoma Antibodies Camidanlumab tesirine

In this video, Alex Herrera, MD, City of Hope, Duarte, CA, shares some updates from a Phase II study evaluating the use of camidanlumab tesirine in patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL). This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Alex Herrera

1:26
The safety and efficacy of alloSCT following CAR-T cell therapy for large B-cell lymphoma
Alex Herrera • 29 Sep 2022
1:27
Treatment options for patients with Hodgkin lymphoma who progress after brentuximab vedotin
Alex Herrera • 29 Sep 2022
0:54
Atezolizumab with R-GEMOX in patients with transformed DLBCL
Alex Herrera • 13 Dec 2021
1:15
Pembrolizumab plus vorinostat in patients with Hodgkin lymphoma refractory to prior PD-1 blockade
Alex Herrera • 13 Dec 2021

Related Videos

2:25
Biomarkers of progression and risk stratification in asymptomatic Waldenström's macroglobulinemia
Mark Bustoros • 27 Sep 2023
2:09
Using lineage tracing to define responding CAR T-cells in patients with LBCL
Zinaida Good • 9 Apr 2024
4:34
Access to CAR-T in minority patients with lymphoma in the US: a retrospective analysis
Marco Ruella • 9 Apr 2024
1:51
Investigating resistance mechanisms to bispecific antibodies and CAR-T in patients with lymphoma
Pau Abrisqueta • 5 Apr 2024
The content of VJHemOnc is intended for healthcare professionals